Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI claim is directly supported by the provided FDA label for TZIELD viral reactivation (EBV/CMV), including prior evaluation, contraindication in immunocompromised/active infection, monitoring through at least 2 months post-infusion, and discontinuation if suspected/confirmed.
Category Scores
Accurate Statements
TZIELD can cause serious, life-threatening viral reactivation including EBV and CMV.
5.1 Viral Reactivation; 17 Patient Counseling (Viral Reactivation subsection)
Reactivation may occur during and within 2 months of TZIELD treatment.
5.1 Viral Reactivation
Patients who are immunocompromised (including patients with Down syndrome) may be at increased risk.
5.1 Viral Reactivation
TZIELD is contraindicated in patients who are immunocompromised or have active viral infection such as EBV or CMV.
4 Contraindications; 5.1 Viral Reactivation; 2.2 Laboratory and Infection Evaluation
Prior to initiating treatment, evaluate patients for active EBV/CMV infection using viral load testing (e.g., PCR).
2.2 Laboratory and Infection Evaluation, and Vaccination Prior to Initiation; 5.1 Viral Reactivation
During treatment and for at least 2 months after the last infusion, monitor for signs/symptoms of viral reactivation; if suspected, discontinue TZIELD and obtain viral load promptly.
5.1 Viral Reactivation; 2.6 Recommended Monitoring During Treatment
If viral reactivation is confirmed, permanently discontinue TZIELD.
5.1 Viral Reactivation
Patient counseling: contact provider immediately for symptoms of viral reactivation during treatment and for at least 2 months after TZIELD.
17 Patient Counseling Information (Viral Reactivation subsection)
Unsupported Statements
Contradictions
Important Omissions
The AI did not explicitly mention label detail that some diagnostic tests (e.g., rapid heterophile antibody testing) may give inaccurate results following TZIELD.
Importance:
Low
The AI did not explicitly mention label detail that the majority of serious cases occurred in patients who continued TZIELD despite persistent, severe lymphopenia, and that duration of severe lymphopenia may be prolonged in adults.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
No contradictory or unsupported safety claims were made; statements about risk, contraindications, evaluation, monitoring duration, and discontinuation are aligned with the provided label text.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Minor label details not mentioned (e.g., potential diagnostic test inaccuracies; lymphopenia-related context).
Suggested Improvement
When summarizing viral reactivation management, optionally include the label note about diagnostic test limitations post-TZIELD and the lymphopenia context if relevant to the summary's purpose.